Second Genome, Inc., a South San Francisco, CA-based biopharmaceutical company developing novel medicines through innovative microbiome science, closed a $42.6m Series B funding.
The round was co-led by Pfizer Venture Investments and Roche Venture Fund with participation from new investors Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and Mayo Clinic, as well as existing investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, Ph.D. In conjunction with the new financing, Elaine Jones, Ph.D., Executive Director of Pfizer Venture Investments, and Carole Nuechterlein, Head of Roche Venture Fund, will join Second Genome’s Board of Directors.
Led by Peter DiLaura, CEO, Second Genome leverages a microbiome discovery platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites from the microbiome that play a causal role in human disease and wellness.
The company, which has raised $59m in total, intends to use the funds to expand the Second Genome Microbiome Discovery Platform in a range of indications associated with barrier function, insulin sensitivity, and immune regulation, and to advance the clinical investigation of SGM-1019, a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in ulcerative colitis, through human proof-of-concept studies.